Digital therapeutics

REPLY: Value Based Medicine Is Born, the Platform Created by Laife Reply for IEO That Makes Patient Care Increasingly Personalised and Appropriate

Retrieved on: 
Monday, April 22, 2024
Technology, Medical Devices, Health Technology, Software, Internet, Health, General Health, Data Management, Artificial Intelligence, Society, Big data, IEO, Digital therapeutics, Health communication, Probability, AI, Elective surgery, Breast, CDP, Insurance, Research, STAR, Pathology, Science, Cloud computing, Intelligence, Drug discovery, Digital, Natural language, Digital health, VBM, Machine learning, Patient, European Institute, Medical imaging, Tangibility, Value, Natural language processing, EXM, Quality of life

The project by Laife Reply and IEO embodies the principles of value-based medicine.

Key Points: 
  • The project by Laife Reply and IEO embodies the principles of value-based medicine.
  • It implements, in a software platform, methods for measuring the improvement of patient care outcomes.
  • The AI tools adopted allow dynamically defining predictive models for each patient, effectively creating a personalised value measurement pathway.
  • Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media.

Digital Therapeutics Market Global and Regional Analysis and Forecast, 2023-2033: Utilization of AI and ML with Digital Therapeutics Growing in Prominence - ResearchAndMarkets.com

Retrieved on: 
Friday, April 12, 2024
General Health, Mental Health, Health, Physical Therapy, Telemedicine, Virtual Medicine, Digital therapeutics, Tradition, Investment, Risk, Country, Region, Software, Health care, Diabetes, Privacy, Digital, Therapy, Pain management, Patient, Data collection, Self-management, Hypertension, Rehabilitation, Security, Behavior, Algorithm, Growth, Global health

Multiple Benefits Provided by Digital Therapeutics over Traditional Treatment: The adoption of digital therapeutics is surging due to their personalized, technology-driven approach to managing various conditions.

Key Points: 
  • Multiple Benefits Provided by Digital Therapeutics over Traditional Treatment: The adoption of digital therapeutics is surging due to their personalized, technology-driven approach to managing various conditions.
  • Continuous Technological Advancements Driving the Adoption of Digital Therapeutics: Digital therapeutics is rising, fueled by technology and widespread smartphones.
  • Increasing Demand for Cost-Effective Solutions Creating a Demand for Digital Therapeutics: As healthcare costs are increasing, digital therapeutics rise as a cost-effective alternative.
  • Rising Fundings and Investment in Digital Therapeutics: The digital therapeutics market is experiencing an investment boom, propelling its growth and paving the way for healthcare advancements.

Northeast Delta HSA partners with Department of Health, Foundation for Wellness to host webinar series "Utilizing Digital Therapeutics"

Retrieved on: 
Wednesday, March 13, 2024
Single-frequency network, Health, Information technology, Digital, Partnership, Physician, Diabetes, DSM-IV codes, Knowledge, Lead, Research, CME, Therapy, Wellness, Digital technology, Thibodeaux, Cholesterol, Multimedia, Nursing, Social, Digital therapeutics, Hypertension

MONROE, La., March 13, 2024 /PRNewswire-PRWeb/ -- Northeast Delta Human Services Authority (NEDHSA), in partnership with the Louisiana Department of Health and Foundation for Wellness, announced a new webinar series on Utilizing Digital Therapeutics (DTx). This series will delve into the power of Digital Therapeutics, an evidence-based software intervention that can prevent, manage, and treat various behavioral health conditions. The six-part webinar series will occur between March and August 2024.

Key Points: 
  • Northeast Delta Human Services Authority (NEDHSA), in partnership with the Louisiana Department of Health and Foundation for Wellness, announced a new webinar series on Utilizing Digital Therapeutics (DTx).
  • This series will delve into the power of Digital Therapeutics, an evidence-based software intervention that can prevent, manage, and treat various behavioral health conditions.
  • MONROE, La., March 13, 2024 /PRNewswire-PRWeb/ -- Northeast Delta Human Services Authority (NEDHSA), in partnership with the Louisiana Department of Health and Foundation for Wellness, announced a new webinar series on Utilizing Digital Therapeutics (DTx).
  • This series will delve into the power of Digital Therapeutics, an evidence-based software intervention that can prevent, manage, and treat various behavioral health conditions.

NCPDP Foundation Opens Its Call for Grant Proposals, Due April 30

Retrieved on: 
Wednesday, February 28, 2024
Innovation, Digital therapeutics, Pharmacogenomics, Social, Pharmacist, Chesley Bonestell, MST, Health, Patient safety, Fund, Medicine, HL7, Trustee, Arrangement, Request, Standard, Value, Role, Single-frequency network, Health equity, Pharmaceutical industry

SCOTTSDALE, Ariz., Feb. 28, 2024 /PRNewswire-PRWeb/ -- The NCPDP Foundation Board of Trustees announced its call for grant proposals that demonstrate the value of NCPDP standards in supporting the expanded role of pharmacists, patient safety, access to care, and coordination of care and innovation. Proposals must meet the grant proposal requirements and be submitted electronically by 5:00 p.m. MST on April 30, 2024, to be considered for the current grant funding cycle.

Key Points: 
  • SCOTTSDALE, Ariz., Feb. 28, 2024 /PRNewswire-PRWeb/ -- The NCPDP Foundation Board of Trustees announced its call for grant proposals that demonstrate the value of NCPDP standards in supporting the expanded role of pharmacists, patient safety, access to care, and coordination of care and innovation.
  • Proposals must meet the grant proposal requirements and be submitted electronically by 5:00 p.m. MST on April 30, 2024, to be considered for the current grant funding cycle.
  • Grant projects must benefit at least one of the NCPDP Foundation strategic initiatives: expanding the role and value of the pharmacist ; expanding patient access to care ; enhancing patient safety ; and empowering coordination of care and innovation, its newest strategic initiative.
  • To submit a grant proposal, complete and submit the Request for Funding form along with supplemental material by 5:00 p.m. MST on April 30, 2024.

Digital Therapeutics (DTx) Market Worth $21.9 Billion | MarketsandMarkets™

Retrieved on: 
Tuesday, January 23, 2024
Diabetes, Obesity, Digital therapeutics, Market development, Patient, Research, Incidence, Pulse, Diet, Roe, Growth, Digital, Software, B2B, Single-frequency network, Investment, Habit, Conditional sentence, Prevalence, Therapy, Substance abuse, Prediabetes, Direct-to-consumer, Pharmaceutical industry

The sales channel segment in the digital therapeutics market is categorized into business-to-business (B2B) and business-to-customer (B2C).

Key Points: 
  • The sales channel segment in the digital therapeutics market is categorized into business-to-business (B2B) and business-to-customer (B2C).
  • Digital Therapeutics (DTx) Market Dynamics:
    Key Market Players of Digital Therapeutics (DTx) Industry:
    Prominent players in the digital therapeutics market include Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Biofourmis (US), Better Therapeutics, Inc (US), Amalgm Rx (US), CogniFit Inc (US), Headspace Health (US), Propeller Health (US), Virta Health Corp (US), 2Morrow, Inc. (US), Realizedcare (US), Canary Health (US), Twill Inc. (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt.
  • Market Development: Comprehensive information detailing lucrative market – the report analyses the digital therapeutics market across various regions as well as countries.
  • Market Diversification: Exhaustive information about new software and programs, untapped geographies, recent developments, and investments in the digital therapeutics market.

National Sleep Foundation Launches SleepTech® Network

Retrieved on: 
Tuesday, January 9, 2024
National Sleep Foundation, Digital therapeutics, Mobility, Sleep, Health, Booth, NSF, Waymo, Samsung Health, Therapy, Doctor of Philosophy, Organization, Education, Pharmaceutical industry

LAS VEGAS, Jan. 9, 2024 /PRNewswire/ -- The National Sleep Foundation (NSF) today launched its SleepTech® Network, a new community forum for stakeholders across the sleep technology industry. The announcement comes from CES® in Las Vegas, a trade show that showcases the entire tech landscape. NSF is exhibiting at Booth 8604 in the North Hall in Tech East.

Key Points: 
  • LAS VEGAS, Jan. 9, 2024 /PRNewswire/ -- The National Sleep Foundation (NSF) today launched its SleepTech® Network , a new community forum for stakeholders across the sleep technology industry.
  • NSF's SleepTech Network benefits members through education, insights, and access, including to NSF resources and each other.
  • Each organization can stay informed and up-to-date with the latest NSF research and data on sleep health technology, while network members learn about advances with other professionals in the field of SleepTech, discuss sleep technology issues and opportunities, and interact with peers at NSF-hosted educational events.
  • NSF has promoted positive sleep health through published expert recommendations, consensus guidelines, technology standards, and easy-to-use tips and tools to improve sleep.

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors

Retrieved on: 
Friday, December 1, 2023
Digital therapeutics, Johnson & Johnson, Biotechnology, GE Research, Autoimmunity, Rheumatology, Internal medicine, Inflammation, Therapy, University, Medical college, Scleroderma, Publication, Patient, University of Toledo, Janssen Pharmaceuticals, Pharmaceutical industry

NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D.

Key Points: 
  • NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D.
  • to the Akari Board of Directors.
  • “Samir is a long-time investor in Akari and brings to us broad life sciences experience and a track record of multiple successful startup companies.
  • I am pleased to welcome him to our Board of Directors at this important time in our company’s development,” said Ray Prudo, M.D., Akari Chairman.

Dx&Vx co-develops a bio-healthcare big data platform with LG CNS

Retrieved on: 
Wednesday, December 20, 2023
Cloud, Google Cloud, Single-frequency network, Stem cell, Digital, Digital therapeutics, Medicine, CVS, Drug development, Research, CDSS, Disease, Blood, Tissue, DNA, Cancer, CDX, AI, GSK, Artificial intelligence, LG CNS, Biomarker, Therapy, LG, Medical device

SEOUL, South Korea, Dec. 20, 2023 /PRNewswire/ -- Dx&Vx will develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS.

Key Points: 
  • Dx&Vx recently announced on the 18th that it has signed a contract with LG CNS to jointly develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS.
  • Dx&Vx is set to introduce an AI-driven digital medical and clinical data platform through its collaboration with LG CNS.
  • LG CNS will provide the AI and big data technologies needed to build the platform.
  • Starting with the joint development, Dx&Vx plans to strengthen its collaboration with LG CNS to develop innovative bio-healthcare solutions based on its biomedical big data platform.

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

Retrieved on: 
Thursday, November 16, 2023
Health, PNE, Acquisition, Chronic pain, Digital therapeutics, PatientsLikeMe, Hospital, Patient, Medication, Movement, Fear, Therapy, Massachusetts General Hospital, Pain, Mindfulness, VR, DSM-IV codes, Quality of life, Single-frequency network, Education, Poultry farming, Nursing

NASHVILLE, Tenn. and AACHEN, Germany, Nov. 16, 2023 /PRNewswire/ -- BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern Health, a virtual chronic pain management program, today announced the signing of an agreement to merge their businesses and create a new digital care management solution for chronic pain. The new offering will be branded as RealizedCare, and strives to meet the increased demand for evidence-based, more scalable, impactful and economically viable solutions for a range of mental and behavioral health burdens, beginning with chronic pain.

Key Points: 
  • RealizedCare introduces an advanced care management platform powered by DTx technology.
  • The platform's approach, which combines DTx with traditional wraparound services, will unlock value-based chronic pain management at scale.
  • "Chronic pain is on the rise globally and the demand for holistic, multi-modal care via digital solutions is growing.
  • "We are thrilled to join RealizedCare and to enable this new offering, which supercharges the scalability and economic viability of traditional care management programs," said Brad Lawson, CEO, Fern Health.

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

Retrieved on: 
Thursday, November 16, 2023
Health, PNE, Acquisition, Chronic pain, Digital therapeutics, PatientsLikeMe, Hospital, Patient, Medication, Movement, Fear, Therapy, Massachusetts General Hospital, Pain, Mindfulness, VR, DSM-IV codes, Quality of life, Single-frequency network, Education, Poultry farming, Nursing

NASHVILLE, Tenn. and AACHEN, Germany, Nov. 16, 2023 /PRNewswire/ -- BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern Health, a virtual chronic pain management program, today announced the signing of an agreement to merge their businesses and create a new digital care management solution for chronic pain. The new offering will be branded as RealizedCare, and strives to meet the increased demand for evidence-based, more scalable, impactful and economically viable solutions for a range of mental and behavioral health burdens, beginning with chronic pain.

Key Points: 
  • RealizedCare introduces an advanced care management platform powered by DTx technology.
  • The platform's approach, which combines DTx with traditional wraparound services, will unlock value-based chronic pain management at scale.
  • "Chronic pain is on the rise globally and the demand for holistic, multi-modal care via digital solutions is growing.
  • "We are thrilled to join RealizedCare and to enable this new offering, which supercharges the scalability and economic viability of traditional care management programs," said Brad Lawson, CEO, Fern Health.